How Much Does Mounjaro Cost in Indiana in 2026?

Mounjaro Retail Price in Indiana

The manufacturer list price for Mounjaro set by Eli Lilly is $1,023 per month, and Indiana retail pharmacies largely mirror that figure in 2026. This price applies regardless of dose. Whether a patient fills their first 2.5 mg pen or a maintenance 15 mg pen, the per-box list price stays the same across all five dosing tiers approved in the Mounjaro prescribing label.

Retail pharmacy pricing in Indiana does not vary much between chains. CVS, Walgreens, and Kroger pharmacy locations across Indianapolis, Fort Wayne, and Evansville all price Mounjaro near or at the $1,023 list. Independent pharmacies occasionally price a few dollars lower, but meaningful savings at the retail counter require insurance, a manufacturer coupon, or a compounding alternative.

Tirzepatide is a dual GIP/GLP-1 receptor agonist that the FDA approved in May 2022 for type 2 diabetes under the brand name Mounjaro [1]. In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.37% from baseline versus 1.86% for semaglutide 1 mg, with co-primary endpoints of HbA1c reduction and weight change both reaching statistical significance (P<0.001 for superiority) [2]. That glucose-lowering and weight-loss profile drives demand across Indiana, where roughly 12.1% of adults carry a diabetes diagnosis according to CDC surveillance data.

The bottom line: without any form of coverage or discount, a patient in Indiana will pay about $12,276 per year out of pocket for brand-name Mounjaro.

Indiana Medicaid Coverage for Mounjaro

Indiana Medicaid covers Mounjaro strictly for type 2 diabetes with prior authorization. It does not cover tirzepatide for weight management. Patients prescribed Mounjaro off-label for obesity will receive a claim denial through the Indiana Health Coverage Programs (IHCP) formulary.

Prior authorization requires documentation of a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), a recent HbA1c value, and evidence that first-line therapy with metformin was tried or is contraindicated. Approvals typically run for 12 months before renewal. The Indiana Family and Social Services Administration (FSSA) publishes its preferred drug list quarterly, and tirzepatide has remained in the "non-preferred, PA required" tier since its addition.

For Indiana Medicaid enrollees seeking tirzepatide specifically for weight loss, the pathway is limited. Zepbound (tirzepatide's obesity-indication brand) is not on the IHCP formulary. The American Association of Clinical Endocrinology (AACE) 2023 obesity treatment algorithm lists tirzepatide as a first-line pharmacotherapy option for patients with BMI ≥30 or BMI ≥27 with a weight-related comorbidity [3], but Medicaid formulary inclusion has not followed that recommendation in Indiana.

Patients on Indiana Medicaid who have both type 2 diabetes and obesity may still qualify for coverage by framing the prescription around glycemic control rather than weight management. The prescribing clinician should document HbA1c targets as the primary treatment objective.

Commercial Insurance Coverage in Indiana

Most major commercial insurers in Indiana cover Mounjaro for type 2 diabetes. Coverage for weight management varies and is changing rapidly. Anthem Blue Cross Blue Shield (Indiana's largest commercial insurer), UnitedHealthcare, and CareSource all include Mounjaro on formulary for type 2 diabetes, typically at a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) position.

Prior authorization is standard. Insurers generally require the same clinical documentation Medicaid does: confirmed T2D diagnosis, baseline HbA1c, and trial of metformin. Some plans add a step-therapy requirement for a GLP-1 such as semaglutide before approving tirzepatide.

Copays with commercial insurance range widely. Tier 3 placement may carry a $50 to $75 copay, while Tier 4 or specialty-tier placement can mean 25% to 33% coinsurance, translating to $250 to $340 per fill. Patients hitting those higher cost-sharing tiers should stack the Eli Lilly savings card on top of their insurance benefit, which is discussed below.

For weight management coverage under commercial plans, the picture is more nuanced. Employer-sponsored plans in Indiana are not required by state law to cover anti-obesity medications. Self-insured employer plans (governed by ERISA, not state mandates) set their own formulary rules. Dr. Robert Kushner, a professor of medicine at Northwestern who has published extensively on obesity pharmacotherapy, noted in a 2024 Obesity Society panel: "The single biggest barrier to GLP-1 access in the Midwest is employer-plan formulary exclusions for weight management indications."

Patients should call the number on the back of their insurance card and ask two specific questions: (1) Is tirzepatide/Mounjaro on formulary for my plan? (2) What is the prior authorization criteria and expected copay tier?

The Eli Lilly Savings Card: How It Works in Indiana

Eli Lilly offers the Mounjaro Savings Card, which reduces the out-of-pocket cost to as low as $25 per monthly fill for commercially insured patients. The card covers up to $150 in savings per 30-day prescription.

Eligibility criteria are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, or Tricare), a valid Mounjaro prescription, and must fill at a participating pharmacy. Nearly all chain and independent pharmacies in Indiana accept the card. It activates at the point of sale when the pharmacist processes it as a secondary payer after running the primary insurance claim.

There is a maximum annual benefit. Eli Lilly caps total savings at $1,800 per calendar year per patient, which works out to $150 per month for 12 fills. If a patient's copay after insurance is $200, the card covers $150, leaving a $50 residual. If the copay is $25 or less, the card may not provide additional value.

Patients without insurance do not qualify for the standard savings card. Eli Lilly previously offered a separate cash-pay program that capped costs at $575 per month for uninsured patients, but availability of that program fluctuates. Check the Mounjaro website directly or call Lilly's patient support line at 1-800-545-6962 for the most current uninsured pricing.

One important note: the savings card does not apply to Zepbound, Lilly's separate tirzepatide product approved for chronic weight management. Mounjaro and Zepbound are the same molecule at the same doses, but they have distinct NDC numbers and distinct coupon programs.

Compounded Tirzepatide in Indiana: Legality, Cost, and Access

Compounded tirzepatide is legal in Indiana when dispensed by a licensed 503A compounding pharmacy with a valid patient-specific prescription. The average price across Indiana 503A pharmacies in 2026 is approximately $249 per month, representing a 76% savings versus the brand-name product.

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound medications for individual patients based on a prescriber's order [4]. Indiana's Board of Pharmacy oversees 503A pharmacies operating within the state. These pharmacies source pharmaceutical-grade tirzepatide active ingredient and compound it into subcutaneous injection form.

The FDA's stance on compounded tirzepatide has been a moving target. Tirzepatide appeared on the FDA drug shortage list in late 2023, which expanded compounding access under federal law. The shortage status has since been revisited, and compounding pharmacies have challenged removal attempts in federal court. As of mid-2026, compounded tirzepatide remains available from 503A pharmacies in Indiana, though patients should verify current regulatory status before initiating therapy.

Quality is the primary concern with compounded products. Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, told Endocrine Society members: "Patients considering compounded GLP-1 agonists must confirm their pharmacy holds current state licensure, submits to third-party potency and sterility testing, and provides beyond-use dating consistent with USP 797 standards."

Patients in Indiana can access compounded tirzepatide through in-state 503A pharmacies or through telehealth platforms that partner with out-of-state 503A pharmacies licensed to ship into Indiana. The prescription must come from a provider licensed in Indiana or holding a valid multi-state license.

Telehealth Access to Mounjaro in Indiana

Indiana allows telehealth prescribing of Mounjaro and compounded tirzepatide. No in-person visit is required for the initial prescription under current Indiana telehealth law.

Indiana Code § 25-1-9.5 governs telehealth practice in the state. Prescribers must hold an active Indiana medical license (or be authorized through the Interstate Medical Licensure Compact, of which Indiana is a member state). Audio-video encounters satisfy the standard of care for initiating GLP-1 therapy, including tirzepatide.

Telehealth platforms operating in Indiana typically charge $99 to $199 for an initial consultation and $49 to $99 for follow-up visits. These fees are separate from the medication cost. Some platforms bundle the consultation fee into the compounded tirzepatide price, offering an all-in monthly cost of $299 to $399 that includes the provider visit, the compounded medication, and shipping.

Patients using telehealth to obtain brand-name Mounjaro will still fill at a retail pharmacy and face the same $1,023 list price (minus insurance and savings card benefits). The telehealth route is most cost-effective for patients pursuing compounded tirzepatide, where the combined provider-plus-medication cost often comes in below the brand copay for patients on high-deductible health plans.

How to Find the Lowest Mounjaro Price in Indiana

The cheapest legal path to tirzepatide in Indiana depends on the patient's insurance status and diagnosis.

Commercially insured with type 2 diabetes: Use the Mounjaro prescription through insurance, then apply the Eli Lilly savings card. Expected out-of-pocket: $25 to $75 per month at most Indiana pharmacies. This is the lowest-cost pathway for most Hoosiers.

Commercially insured for weight management (no T2D): If the employer plan excludes weight-loss drugs, the insurance claim will deny. The patient can then use a compounded tirzepatide prescription through a 503A pharmacy for approximately $249 per month, or pay cash for brand Mounjaro at $1,023 per month.

Indiana Medicaid enrollee with T2D: File the prior authorization. If approved, the copay is $0 to $3 depending on the Medicaid plan tier. If denied, appeal with supporting clinical documentation per AACE guidelines [3].

Uninsured: Compounded tirzepatide at $249 per month is the most affordable option. Eli Lilly's patient assistance program (Lilly Cares) may also provide free brand-name Mounjaro to patients below 400% of the federal poverty level [5].

GoodRx and similar discount platforms show Indiana cash prices for brand Mounjaro ranging from $960 to $1,050 depending on location and dose. These coupons do not stack with insurance.

Comparing Mounjaro Costs: Indiana vs. Neighboring States

Indiana's Mounjaro pricing sits at the national average. The $1,023 per month list price is identical in Ohio, Illinois, Michigan, and Kentucky because Eli Lilly sets a uniform national wholesale acquisition cost [1].

Where states differ is Medicaid coverage. Illinois Medicaid covers tirzepatide for both type 2 diabetes and, as of 2025, for weight management through a managed care carve-out. Ohio Medicaid covers for T2D only, matching Indiana. Michigan Medicaid added limited weight-management coverage in late 2025 for patients with BMI ≥40 and at least one obesity-related comorbidity.

Compounded tirzepatide pricing also varies by state due to pharmacy licensing and market density. Indiana's $249 average sits below the national average of roughly $275 per month, likely reflecting proximity to compounding supply chains in the Indianapolis metro area.

For Indiana residents near state borders, there is no cost advantage to filling across state lines. The brand price is the same, and compounding pharmacy regulations require the prescription to originate from a provider licensed in the dispensing state (or a compact state).

Clinical Outcomes That Justify the Cost

Tirzepatide's dual GIP/GLP-1 mechanism produces outcomes that exceed single-agonist GLP-1 drugs. Understanding the clinical data helps patients and providers weigh whether the cost is proportionate to the benefit.

In SURPASS-2 (N=1,879), participants on tirzepatide 15 mg lost a mean of 12.4 kg compared to 6.2 kg for semaglutide 1 mg over 40 weeks [2]. The HbA1c reductions were 2.37% versus 1.86%, respectively, with 51% of tirzepatide patients achieving an HbA1c below 5.7% (a non-diabetic threshold) compared to 20% on semaglutide. Both between-group differences reached statistical significance (P<0.001).

The SURMOUNT-1 trial (N=2,539) studied tirzepatide specifically for obesity in adults without diabetes. At 72 weeks, the 15 mg dose produced 22.5% mean body weight reduction versus 2.4% for placebo [6]. That magnitude of weight loss approaches what was historically achievable only through bariatric surgery.

A 2023 cost-effectiveness analysis published in Annals of Internal Medicine modeled tirzepatide for type 2 diabetes at $1,023 per month and found an incremental cost-effectiveness ratio (ICER) of $121,000 per quality-adjusted life year (QALY) compared to semaglutide 1 mg [7]. The commonly cited willingness-to-pay threshold in the U.S. is $100,000 to $150,000 per QALY, placing tirzepatide at the borderline of cost-effectiveness at list price. With insurance negotiated rates or compounded pricing, the ICER improves substantially.

Common side effects include nausea (reported in 12% to 18% of patients across SURPASS trials), diarrhea, decreased appetite, and injection-site reactions [1]. These are generally mild to moderate and tend to diminish after the dose-titration phase.